The Impedimed (ASX:IPD) share price is up 10% on trial success

More good news out of the medical technology company's camp today.

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Impedimed Limited (ASX: IPD) share price is making good ground today, having climbed 10% from the market open to now trade at 16.5 cents.

Impedimed shares are again on the move after coming out of a trading halt that was requested before the start of trade today.

Here's what we know.

What was announced?

The company announced positive readouts from its recently completed PREVENT pivotal trial involving cancer-related lymphoedema patients across the US and Australia.

It's the end of a 6-year journey for the PREVENT trial which has been examining the effectiveness of Impedimed's L-Dex technology in reducing the onset of chronic lymphoedema.

The aim of the study was to determine if early intervention in patients with lymphoedema using "bioimpedance spectroscopy (BIS)" resulted in a lower rate of disease progression. It was compared to using a tape measure to detect the presence of excess fluid.

The study findings indicate that in patients with early detection using L-Dex, the protocol "resulted in a lower rate of progression to chronic disease than patients with early detection from volume measures using a tape measure".

This, it claims, is a result that is statistically significant. The study collected data from 1,200 patients followed for up to three years across 13 hospitals in both countries.

The results showed that in patients using L-Dex with early detection lymphoedema, the intervention resulted in a 7.9% rate of chronic lymphoedema compared to 19.2% in the tape measure group.

This represents an absolute reduction of 11.3% and a relative reduction of 59%.

In addition to these findings, "92% of patients with early detection cancer-related lymphoedema using L-Dex and intervention did not progress [to the chronic stages]".

What did Impedimed conclude from its results?

The company surmised that its methodology "should be a standard approach for prospective breast cancer-related lymphoedema (BCRL) surveillance".

It also states its process is more specific in detecting lymphoedema than a tape measure "as it had fewer triggers and longer times to intervention trigger", based on the data.

In conclusion, the company said that when compared to a tape measure, the BIS screening method results in a more precise identification of patients more likely to benefit from early compression intervention.

For reference, lymphoedema is often managed using compression garments to mobilise the excess extracellular fluid.

Speaking on the announcement, Impedimed CEO Richard Carreon said the results were "significant not just for Impedimed, but for cancer patients at risk of lymphoedema".

Touching more on the results, Carreon added:

This study is consistent with the previous studies showing regular monitoring with L-Dex and simple intervention substantially reduce the risk of developing cancer-related lymphoedema. What differentiates this study is, for the first time, we have a level I randomised controlled trial of sufficient size and duration to result in a statistically significant difference between the outcomes using L-Dex and Tape Measure.

The Impedimed share price has rallied 22% in the past week, extending its gains in the last month to over 50%.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Happy shareholders clap and smile as they listen to a company earnings report.
Share Gainers

Why Brainchip, Cooper Energy, Core Lithium, and Neuren shares are roaring higher today

These shares are having a good time on hump day. But why?

Read more »

Unsure man analysing data on laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors endured a rough day of trading this Tuesday.

Read more »

A mature-aged couple high-five each other as they celebrate a financial win and early retirement
Share Gainers

Why this ASX 300 stock is soaring 12% after a disastrous year

This company has had a dramatic reversal of fortunes this Tuesday...

Read more »

A young woman wearing overalls and a yellow t-shirt kicks one leg in the air showing excitement over the latest ASX 200 shares to hit 52-week highs
Share Gainers

Why Core Lithium, Imugene, Lifestyle Communities, and Mineral Resources shares are charging higher

These shares are having a good session. What's going on?

Read more »

A young woman smiles as she rides a zip line high above the trees.
Share Gainers

4 ASX All Ords shares up 315% to 682% in a year!

Investors have sent these ASX All Ords shares flying higher. But why?

Read more »

Man standing on rock next to turquoise salt lagoon.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors enjoyed a great start to the trading week today.

Read more »

Smiling couple looking at a phone at a bargain opportunity.
Share Gainers

Why Austal, Breville, Telix, and Westgold shares are pushing higher today

These shares are starting the week positively. But why?

Read more »

A couple sits on a sofa, each clutching their heads in horror and disbelief, while looking at a laptop screen.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors endured a rough Friday to close the trading week today.

Read more »